Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody-based therapies for cancer and other serious diseases. Its American Depositary Shares trade on Nasdaq under the ticker GMAB. The company's technology platforms include DuoBody for bispecific antibodies and HexaBody for enhanced antibody activity.
For most of its history, Genmab operated primarily as an innovator that licensed its antibodies to larger pharmaceutical companies and collected royalties. Its largest revenue source is DARZALEX (daratumumab), marketed by Johnson & Johnson, along with royalties on Kesimpta sold by Novartis. In recent years Genmab has pivoted toward wholly or partly owned commercial products, including EPKINLY/TEPKINLY (with AbbVie) and TIVDAK, while building out a proprietary late-stage pipeline through acquisitions such as the roughly $8 billion Merus deal. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, GMAB rose from a closing price of about $36.89 to $51.36, a gain of approximately 39%. The move was not gradual: much of the advance came in two sharp bursts in late October, with the stock closing near $57 before consolidating back to the low-$50s as investors took profits following the initial surge.
The broader quarter tells a similar but even stronger story. From a closing level of about $31.34 in mid-August, the shares have advanced roughly 64%. This multi-month climb lifted Genmab to an all-time high and positioned the company as one of the top performers in Denmark's C25 index, as a series of clinical milestones steadily reduced the risk associated with its late-stage pipeline.
The dominant catalyst was a near-sweep of positive Phase 3 readouts across three core programs. In early October, Genmab and AbbVie reported that epcoritamab (EPKINLY) plus R-CHOP reduced the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma. Later in the month, the antibody-drug conjugate Rina-S showed a 71% reduction in the risk of progression or death in platinum-resistant ovarian cancer.
The largest single move came on October 28, when Genmab announced that petosemtamab combined with Merck's Keytruda cut the risk of death by 50% versus Keytruda alone in first-line head and neck cancer. The shares jumped about 28% in a single session on heavy volume, reaching a record high. Because Genmab owns petosemtamab outright through its Merus acquisition, the result was read by investors as a direct validation of the company's ownership strategy. Analyst activity reinforced the move, with firms including Guggenheim and Leerink Partners raising price targets. Third-quarter earnings reported in early November showed 16% revenue growth to about $1.19 billion, led by royalties and EPKINLY sales, though operating income declined amid higher R&D and integration costs.
The quarterly gain reflects a broader rerating of Genmab's strategy rather than any single event. Investors had long valued the company primarily for its DARZALEX royalty stream, which faces eventual biosimilar competition. The succession of late-stage clinical successes shifted the narrative toward Genmab's growing portfolio of owned assets, reducing the "patent cliff" overhang and encouraging the market to price in a new generation of potential blockbusters.
The Merus acquisition — a high-risk, debt-funded bet on petosemtamab — is now viewed more favorably after the survival data, and the pipeline readouts across lymphoma, ovarian, and head and neck cancers gave the transition to a commercial drugmaker tangible momentum. Strong royalty cash flow continues to fund research while the company scales its own sales infrastructure in the U.S. and Europe.
Several factors will shape GMAB's trajectory in the months ahead. Full petosemtamab data presentations at medical meetings and eventual regulatory engagements are key, since the headline 50% survival benefit came from a first interim analysis and the durability of the effect remains to be confirmed. Investors will also monitor commercial execution for EPKINLY/TEPKINLY and TIVDAK, the pace of DARZALEX royalty growth, and the integration and spending tied to the Merus acquisition.
Macro considerations such as drug-pricing policy, interest-rate-sensitive biotech valuations, and Danish krone currency exposure may also influence the ADR. Continued clinical data, updated analyst price targets, and any shifts in 2026 revenue guidance will be important signposts, alongside the company's stated goal of expanding its owned portfolio's reach toward a much larger patient base over the next decade. From what I see, these elements remain central to the investment case.
In my research process I often turn to Tickeron’s Trending AI Robots for automated trading signals and strategy ideas. The page highlights a curated selection of AI-powered trading bots from a platform that offers hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots appear, giving traders a focused view of strategies that are currently generating notable results. The bots vary widely in strategy, timeframe, and performance metrics, so the page is useful for comparing different automated approaches across the market. If you are interested in adding data-driven signals to your own research workflow, this offers a practical starting point.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
GMAB's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 213 similar instances where the Aroon Indicator showed a similar pattern. In 148 of the 213 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 69%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +5.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 200 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The 10-day RSI Indicator for GMAB moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 26 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMAB as a result. In 62 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for GMAB turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 30 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
GMAB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.536) is normal, around the industry mean (3.498). P/E Ratio (41.866) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (440.869).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.
Industry Biotechnology